Intravenous AN4035

Phase 1

AAdlai Nortye Biopharma Co., Ltd.

Intravenous AN4035 is one of 2 therapeutic programs targeting RAS Mutation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

RAS MutationNot yet recruiting

RAS MutationPhase 1

Not yet recruiting

Competition

Competitive Landscape

1 competitor in RAS Mutation

#DrugCompanyPhaseTrials

Arava

Sanofi

Phase 2

1 2

Intravenous AN4035

AAdlai Nortye Biopharma Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

RAS Mutation

NCT07686445

Clinical

Trials by Indication[1]

RAS Mutation1 trial

A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN4035 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations and Enriched for CEACAM5 Expression

Not yet recruiting·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT07686445·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous AN4035. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intravenous AN4035. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Adlai Nortye Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAdlai Nortye Biopharma Co., Ltd.

Intravenous AN4035

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

RAS Mutation1 trial

References

Drug Info

Quick Facts

Related News